Study Links Medical Cannabis Laws to Stronger Company Performance

A peer-reviewed study¹ of more than 13,000 publicly traded companies has found that firms headquartered in states with legal medical cannabis post higher market valuations, more productive workforces, and more innovation than their counterparts in states that still prohibit it. The catch for anyone reading it as an endorsement of workplace weed is that the authors say the driver isn’t the drug. It’s the talent that legalization attracts.

The paper, from University of Iowa finance professor Tong Yao with co-authors Jue Wang of Nankai University and Shagun Pant of the University of Illinois, tracked corporate results nationwide from 2001 to 2022, comparing the 38 states that have legalized medical cannabis under a patchwork of state-by-state rules against those that have not. It was published in the peer-reviewed finance journal Financial Management, which places the claim in a very different register from the industry-funded economic-impact reports that usually carry the pro-legalization case.

Inside the numbers

Valuations rose in 21 of those 38 states. Gross profit per employee and gross sales per employee each climbed by more than $8,000 in legalizing states relative to those that held out. Patent filings rose 10.4 percent across the legalizing states, and the economic value of those patents increased 22 percent.

Because the productivity figures are measured per employee, they scale with headcount, and the patent results point to a lasting edge in innovation rather than a one-off lift. The effect was not uniform, though: valuations improved in a little more than half the states studied, and the numbers are correlations drawn from a natural experiment rather than a controlled trial. The pattern held regardless of whether a state had a Democratic or Republican governor, which the authors read as evidence that the result tracks the policy itself rather than the politics around it.

Talent, not the plant

Yao is blunt that the finding is not an argument for intoxicated offices. In the Iowa team’s account, medical legalization works as a cultural marker that skilled, mobile workers notice when they decide where to live and work.

“In addition to providing a host of medical benefits, legalizing marijuana can also give the state a ‘cool image,'” Yao said in a statement. “Highly skilled and creative human capital is especially appreciative of open, new, and divergent policies, such as legalized medical marijuana, and that can potentially help states retain and attract more productive and creative workers.”

To test that idea, the researchers tracked the movement of individual inventors across state lines. They found that legalizing states were better both at keeping the inventors they already had and at recruiting new ones from prohibition states. More inventors, and more productive ones, is the mechanism the paper offers for the rise in patents and patent value. The study looked only at medical legalization, not recreational markets, which isolates the effect of the earliest and most modest reform rather than the broader commercial rollout that came later in many states.

Why it matters beyond the cannabis industry

The sample is the broad universe of U.S. public companies, most of which have nothing to do with the plant. That makes the result a statement about state economic competitiveness rather than about the marijuana market itself. For operators and investors used to reading legalization as a question of dispensary licenses and tax receipts, the paper reframes the stakes and treats a medical-cannabis law as a form of industrial policy, one that shapes where high-value companies and their workforces choose to sit. The practical implication for a headquarters or expansion decision is that a state’s cannabis stance now reads as a signal about its labor market, sitting alongside taxes, universities, and cost of living in the calculus of where growth-stage companies locate. It lands as researchers probe the economics of medical cannabis from other directions, including a Colorado study testing whether workers’ compensation should cover it.

It also carries a warning for latecomers. Yao noted that California, the first state to legalize medical use in 1996, saw an early surge in business growth and creativity, and that the effect has weakened as more states followed. The signal loses value once it stops being distinctive. Early movers captured the largest gains, and states passing medical laws now are competing against dozens of others offering the same cultural cue.

That decay is the part worth watching. The research window closes in 2022, before the later wave of federal and adult-use policy change, including the federal reclassification of medical cannabis. What the paper puts on the record is a measurable case that the business argument for medical cannabis reaches well past the industry those laws created, alongside evidence that the payoff for moving first is already shrinking.

References:

^{1. Pant, Shagun; Wang, Jue; and Yao, Tong. “Do Firms Get High? The Impact of Medical Marijuana Legalization on Firm Performance and Corporate Innovation” (2026). Financial Management. https://doi.org/10.1111/fima.70037}